Maze Therapeutics (NASDAQ:MAZE) Shares Gap Down on Insider Selling

Key Points

• Maze Therapeutics' share price gapped down from $23.25 to $22.59 prior to trading on Tuesday, with the last trade recorded at $23.72.
• Analysts have a consensus rating of "Buy" for Maze Therapeutics, with price targets ranging from $17.00 to $50.00.
• The company's most recent earnings report showed a per-share loss of ($0.77), beating expectations by $0.02.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s share price gapped down prior to trading on Tuesday following insider selling activity. The stock had previously closed at $23.25, but opened at $22.59. Maze Therapeutics shares last traded at $23.72, with a volume of 37,505 shares changing hands.

Specifically, Director Richard H. Scheller sold 20,744 shares of the firm's stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Wall Street Analysts Forecast Growth

MAZE has been the subject of several analyst reports. Wedbush assumed coverage on shares of Maze Therapeutics in a research report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price target for the company. BTIG Research upped their price target on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a "buy" rating in a research note on Friday, September 12th. Guggenheim increased their price objective on shares of Maze Therapeutics from $19.00 to $34.00 and gave the stock a "buy" rating in a research note on Monday, September 15th. Wall Street Zen upgraded shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Finally, HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Maze Therapeutics in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $32.67.

Maze Therapeutics Price Performance

The stock's 50-day moving average price is $16.15 and its 200-day moving average price is $12.67.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.02.

Hedge Funds Weigh In On Maze Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund bought a new position in Maze Therapeutics during the first quarter worth about $25,000. CWM LLC purchased a new stake in shares of Maze Therapeutics in the second quarter worth about $28,000. Corebridge Financial Inc. purchased a new stake in Maze Therapeutics in the first quarter valued at approximately $48,000. Legal & General Group Plc raised its stake in Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock valued at $52,000 after purchasing an additional 3,371 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Maze Therapeutics by 452.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock valued at $57,000 after purchasing an additional 3,774 shares in the last quarter.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.